December 13, 2005 -- Insmed won FDA approval for Iplex, a once-a-day oral therapy for growth failure in children; the Insmed announcement had a negative effect on Tercicia, whose Increlex competes for the same patients; CuraGen reported that valafermin failed to meet its Phase II endpoints as a treatment for oral mucositis; GlaxoSmithKline in-licensed a pain drug candidate in early development at Vertex; Medicis decided not to raise its bid for Inamed, receiving instead a $90 million payment from Inamed; the FDA has asked Merck to supply more information about the effectiveness of its oral rotavirus vaccine candidate; at the ASH conference, Biogen Idec presented positive data on Zevalin radioimmunotherapy in various forms of lymphoma; and Favrille said that FavId raised the response rate of Rituxan. The Centient Biotech 200™ was 19 points higher at 3975.38, a rise of .49%. More details...
